Amgen Inc. (BCBA:AMGN)

Market Cap	202.54T
Revenue (ttm)	36.62T
Net Income (ttm)	6.37T
Shares Out	n/a
EPS (ttm)	11,742.69
PE Ratio	31.81
Forward PE	14.14
Dividend	207.33 (1.62%)
Ex-Dividend Date	May 16, 2025

Volume	833
Average Volume	3,124
Open	12,700
Previous Close	12,800
Day's Range	12,425 - 12,825
52-Week Range	9,500 - 16,000
Beta	n/a
RSI	60.62
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD